Cargando…

Therapeutic effect of ibrutinib, a selective Bruton’s tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves’ orbitopathy

PURPOSE: Bruton’s tyrosine kinase (BTK) is an essential protein in B-cell antigen receptor (BCR) signaling pathway and is known to be related to pathogenetic effect on B-cell related malignancies and various autoimmune diseases. In this study, we investigated the therapeutic effect of ibrutinib, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyun Young, Chae, Min Kyung, Ko, JaeSang, Kikkawa, Don O., Jang, Sun Young, Yoon, Jin Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754806/ https://www.ncbi.nlm.nih.gov/pubmed/36521376 http://dx.doi.org/10.1371/journal.pone.0279060

Ejemplares similares

The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves’ Orbitopathy
por: Byeon, Hyeong Ju, et al.
Publicado: (2023)

Protein tyrosine phosphatase 1B as a therapeutic target for Graves’ orbitopathy in an in vitro model
por: Byeon, Hyeong Ju, et al.
Publicado: (2020)

Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves’ Orbitopathy
por: Lee, Jihei Sara, et al.
Publicado: (2020)

MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2019)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2021)

Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy
por: Lee, Chae Eun, et al.
Publicado: (2020)

MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves’ orbitopathy by repressing interleukin-2-inducible T-cell kinase
por: Choi, Yeon Jeong, et al.
Publicado: (2022)

Graded Decompression of Orbital Fat and Wall in Patients with Graves' Orbitopathy
por: Lee, Kyou Ho, et al.
Publicado: (2014)

Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves’ Orbitopathy
por: Kim, Bo Yi, et al.
Publicado: (2022)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves’ Orbitopathy
por: Kim, Bo Ram, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
por: Voice, Angus T., et al.
Publicado: (2021)

The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
por: Ratain, Mark J., et al.
Publicado: (2022)

Novel Roles of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy
por: Ma, Chao, et al.
Publicado: (2022)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
por: Dias, Ajoy Lawrence, et al.
Publicado: (2013)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
por: Wang, Jin, et al.
Publicado: (2017)

Effects of Orbital Decompression on Lamina Cribrosa Depth in Patients with Graves' Orbitopathy
por: Seo, Yuri, et al.
Publicado: (2019)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
por: Ping, Lingyan, et al.
Publicado: (2017)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

SAT-421 Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves’ Orbitopathy
por: Wang, Xing, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Quercetin Inhibits IL-1β-Induced Inflammation, Hyaluronan Production and Adipogenesis in Orbital Fibroblasts from Graves' Orbitopathy
por: Yoon, Jin Sook, et al.
Publicado: (2011)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Reasons for revision surgery after orbital decompression for Graves’ orbitopathy
por: Sellari-Franceschini, Stefano, et al.
Publicado: (2008)

Distinctive Features of Orbital Adipose Tissue (OAT) in Graves’ Orbitopathy
por: Zhang, Lei, et al.
Publicado: (2020)

Endoscopic Orbital Decompression for Graves’ Orbitopathy – A Vietnam Study
por: Pham, Thi My Hanh, et al.
Publicado: (2021)

Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves’ orbital fibroblasts
por: Lee, Sung Jun, et al.
Publicado: (2018)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l7dv979kbg4vbovvfvpqkva87g